36例小脑转移瘤外科治疗及预后因素分析

doi:10.19401/j.cnki.1007-3639.2022.04.009

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (4): 357-362.doi: 10.19401/j.cnki.1007-3639.2022.04.009

36例小脑转移瘤外科治疗及预后因素分析

周长帅¹()(), 杨越超¹, 崔欢欢¹, 陈磊¹, 陈鑫¹, 郝斌¹, 童彤², 曹依群¹()()

1.复旦大学附属肿瘤医院神经外科,复旦大学上海医学院肿瘤学系,上海 200032
2.复旦大学附属肿瘤医院放射诊断科,复旦大学上海医学院肿瘤学系,上海 200032

收稿日期:2022-01-19 修回日期:2022-02-20 出版日期:2022-04-30 发布日期:2022-05-07
通信作者: 曹依群 E-mail:zhoucs1682@163.com;gem23@163.com
作者简介:周长帅（ORCID: 0000-0003-3708-6146）,硕士,住院医师 E-mail: zhoucs1682@163.com
基金资助:
国家自然科学基金青年基金(81802494)

Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients

ZHOU Changshuai¹()(), YANG Yuechao¹, CUI Huanhuan¹, CHEN Lei¹, CHEN Xin¹, HAO Bin¹, TONG Tong², CAO Yiqun¹()()

1. Department of Neurosurgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
2. Department of Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2022-01-19 Revised:2022-02-20 Published:2022-04-30 Online:2022-05-07
Contact: CAO Yiqun E-mail:zhoucs1682@163.com;gem23@163.com

摘要/Abstract

关键词: 小脑转移瘤, 手术, Ki-67增殖指数, 生存分析, 预后因素

Key words: Cerebellar metastasis, Surgery, KI-67 index, Survival analysis, Prognostic factors

中图分类号:

R739.41

周长帅, 杨越超, 崔欢欢, 陈磊, 陈鑫, 郝斌, 童彤, 曹依群. 36例小脑转移瘤外科治疗及预后因素分析[J]. 中国癌症杂志, 2022, 32(4): 357-362.

ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun. Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients[J]. China Oncology, 2022, 32(4): 357-362.

图/表 5

表1

图1

表2

图2

图3

参考文献 26

[1]	SUH J H,, KOTECHA R,, CHAO S T, et al. Current approaches to the management of brain metastases[J]. Nat Rev Clin Oncol, 2020, 17(5): 279-299. doi: 10.1038/s41571-019-0320-3
[2]	YOSHIDA S,, TAKAHASHI H. Cerebellar metastases in patients with cancer[J]. Surg Neurol, 2009, 71(2): 184-187; discussion187. doi: 10.1016/j.surneu.2007.10.010
[3]	LEE K J,, JOO W I,, RHA H K, et al. Peritumoral brain edema in meningiomas: correlations between magnetic resonance imaging, angiography, and pathology[J]. Surg Neurol, 2008, 69(4): 350-355; discussion355. doi: 10.1016/j.surneu.2007.03.027
[4]	CHAICHANA K L,, RAO K,, GADKAREE S, et al. Factors associated with survival and recurrence for patients undergoing surgery of cerebellar metastases[J]. Neurol Res, 2014, 36(1): 13-25. doi: 10.1179/1743132813Y.0000000260
[5]	盛舒言,, 胡瑛. 脑转移瘤免疫相关疗效评价标准的研究进展[J]. 中国肺癌杂志, 2021, 24(2): 124-130.
	SHENG S Y,, HU Y. Ongoing evaluation of immune-related response assessment in brain metastases[J]. Chin J Lung Cancer, 2021, 24(2): 124-130.
[6]	GASPAR L,, SCOTT C,, ROTMAN M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J]. Int J Radiat Oncol Biol Phys, 1997, 37(4): 745-751. doi: 10.1016/S0360-3016(96)00619-0
[7]	SPERDUTO P W,, BERKEY B,, GASPAR L E, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1 960 patients in the RTOG database[J]. Int J Radiat Oncol Biol Phys, 2008, 70(2): 510-514. doi: 10.1016/j.ijrobp.2007.06.074
[8]	SPERDUTO P W,, CHAO S T,, SNEED P K, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4 259 patients[J]. Int J Radiat Oncol Biol Phys, 2010, 77(3): 655-661. doi: 10.1016/j.ijrobp.2009.08.025
[9]	李建峰,, 崔凯,, 刘荣举. 37例手术治疗小脑转移瘤预后因素分析[J]. 中国微侵袭神经外科杂志, 2019, 24(10): 456-459.
	LI J F,, CUI K,, LIU R J. Analysis of prognostic factors of surgery for cerebellar metastasis in 37 patients[J]. Chin J Minim Invasive Neurosurg, 2019, 24(10): 456-459.
[10]	SCHACKERT G,, LINDNER C,, PETSCHKE S, et al. Retrospective study of 127 surgically treated patients with multiple brain metastases: indication, prognostic factors, and outcome[J]. Acta Neurochir (Wien), 2013, 155(3): 379-387. doi: 10.1007/s00701-012-1606-8
[11]	周先申,, 万经海. 多发脑转移瘤手术指征及综合治疗探讨[J]. 中国临床医生杂志, 2017, 45(4): 69-72.
	ZHOU X S,, WAN J H. Surgical indications and comprehensive treatment of multiple brain metastases[J]. Chin J Clin, 2017, 45(4): 69-72.
[12]	INARI H,, SUGANUMA N,, KAWACHI K, et al. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer[J]. Breast Cancer, 2017, 24(6): 748-755. doi: 10.1007/s12282-017-0774-z
[13]	SAAD A G,, YEAP B Y,, THUNNISSEN F B, et al. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma[J]. Cancer, 2008, 113(8): 2129-2138. doi: 10.1002/cncr.23826
[14]	BUBB R S,, KOMAKI R,, HACHIYA T, et al. Association of Ki-67, p53, and bcl-2 expression of the primary non-small cell lung cancer lesion with brain metastatic lesion[J]. Int J Radiat Oncol Biol Phys, 2002, 53(5): 1216-1224. doi: 10.1016/S0360-3016(02)02861-4
[15]	SPANBERGER T,, BERGHOFF A S,, DINHOF C, et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases[J]. Clin Exp Metastasis, 2013, 30(4): 357-368. doi: 10.1007/s10585-012-9542-9
[16]	王月坤,, 刘磊,, 陈琬琦, 等. 脑转移瘤患者单纯手术治疗与手术联合术后脑部放疗对比分析[J]. 中国现代神经疾病杂志, 2021, 21(3): 162-169.
	WANG Y K,, LIU L,, CHEN W Q, et al. Comparison of neurosurgery combined brain radiotherapy versus neurosurgery alone for patients with brain metastases[J]. Chin J Contemp Neurol Neurosurg, 2021, 21(3): 162-169.
[17]	BROWN P D,, BALLMAN K V,, CERHAN J H, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(8): 1049-1060. doi: 10.1016/S1470-2045(17)30441-2
[18]	SHAH P P,, FRANKE J L,, MEDIKONDA R, et al. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy[J]. J Neurosurg, 2022, 136(1): 56-66. doi: 10.3171/2020.10.JNS201787
[19]	WANG H J,, WANG Z Q,, ZHANG G W, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations[J]. Cancer Med, 2020, 9(2): 487-495. doi: 10.1002/cam4.2706
[20]	MILLER J A,, KOTECHA R,, AHLUWALIA M S, et al. The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases[J]. Pract Radiat Oncol, 2017, 7(4): e263-e273.
[21]	GADGEEL S,, PETERS S,, MOK T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer: CNS efficacy results from the ALEX study[J]. Ann Oncol, 2018, 29(11): 2214-2222. doi: 10.1093/annonc/mdy405
[22]	FIGURA N B,, RIZK V T,, MOHAMMADI H, et al. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy[J]. Breast Cancer Res Treat, 2019, 175(3): 781-788. doi: 10.1007/s10549-019-05170-7
[23]	FABI A,, ALESINI D,, VALLE E, et al. T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer[J]. Breast, 2018, 41: 137-143. doi: 10.1016/j.breast.2018.07.004
[24]	张佳玲,, 张凤春,, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677.
	ZHANG J L,, ZHANG F C,, XU Y C. Research progress in the systemic treatment for breast cancer with brain metastasis[J]. J Shanghai Jiao Tong Univ Med Sci, 2021, 41(5): 671-677.
[25]	邱娴,, 胡良运,, 周敏, 等. 小剂量贝伐珠单抗治疗肺癌复发脑转移瘤伴难治性瘤周水肿的疗效分析[J]. 中华转移性肿瘤杂志, 2019, 2(4): 25-30.
[26]	杨泽兴,, 王宏伟. 贝伐珠单抗治疗脑转移瘤瘤周水肿的短期疗效观察[J]. 中华神经外科杂志, 2020, 36(8): 837-840.
	YANG Z X,, WANG H W. Short term efficacy of bevacizumab in the treatment of peritumoral edema of brain metastases[J]. Chin J Neurosurg, 2020, 36(8): 837-840.

Factors	n=36
Age/year	58.75±8.99
Female	16 (44.44%)
Extracranial metastasis	23 (63.89%)
Lesions
1	18 (50.00%)
2	10 (27.78%)
≥3	8 (22.22%)
Diameter D/cm
≥3	24 (66.67%)
<3	12 (33.33%)
Location
Cerebellar metastases	19 (52.78%)
Combined supratentorial metastases	17 (47.22%)
Peritumoral edema
Light	16 (44.44%)
Moderate	11 (30.56%)
Severe	9 (25.00%)
Primary tumor
Lung cancer	19 (52.78%)
Breast cancer	7 (19.44%)
Colorectal cancer	4 (11.11%)
Gynecological tumor	2 (5.56%)
Melanoma	2 (5.56%)
Renal carcinoma	1 (2.78%)
Pancreatic cancer	1 (2.78%)
Ki-67 proliferation index
<50%	15 (41.67%)
≥50%	21 (58.33%)
Postoperative targeted therapy	18 (50.00%)
Postoperative radiotherapy	20 (55.56%)

Characteristics	Case (n=36)	Univariate analysis		Multivariate analysis
Characteristics	Case (n=36)	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Age (≥65 years)	9	1.838 (0.727-4.646)	0.198
Gender (male)	20	1.854 (0.747-4.606)	0.183
Extracranial metastasis	23	1.696 (0.656-4.384)	0.276
KPS score≥70	24	0.767 (0.316-1.865)	0.559
Diameter ≥3 cm	24	0.739 (0.287-1.904)	0.531
Multiple lesions (≥3)	8	3.393 (1.371-8.400)	0.008	2.079 (0.516-8.375)	0.303
Combined supratentorial metastases	17	2.334 (0.949-5.739)	0.065	1.517 (0.432-5.332)	0.515
Peritumoral edema (severe)	9	0.524 (0.166-1.659)	0.272
Postoperative radiotherapy	20	0.262 (0.106-0.648)	0.004	0.040 (0.008-0.196)	<0.001
Postoperative targeted therapy	18	0.321 (0.122-0.846)	0.022	0.178 (0.052-0.602)	0.006
Ki-67 proliferation index ≥50%	21	3.543 (1.255-10.002)	0.017	3.772 (1.067-13.336)	0.039

36例小脑转移瘤外科治疗及预后因素分析

Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈玺, 曾晓颖, 陈佳艳, 刘菲, 唐曦. 错配修复蛋白联合血清肿瘤标志物与Ki-67增殖指数对结直肠癌预后的临床价值[J]. 中国癌症杂志, 2022, 32(3): 243-250.
[2]	周明梁, 宋章法, 李振军. 腹部无辅助切口的达芬奇机器人手术切除直肠间质瘤1例[J]. 中国癌症杂志, 2022, 32(1): 75-79.
[3]	王泽洲, 张　扬, 莫　淼, 袁　晶, 周昌明, 沈　洁, 冯小双, 吴浩旋, 李　航, 叶　挺, 胡　鸿, 陈海泉, 郑　莹 . 以医院登记为基础的初诊未转移肺癌患者的转移部位分布及生存分析[J]. 中国癌症杂志, 2021, 31(9): 775-782.
[4]	袁　浩, 蒋晓飞, 游庆华, 朱红波, 叶慧英, 伍　雯, 钱丰源, 钟　明, 李永平 . 甲状旁腺细针穿刺Diff-Quik染色在甲状腺癌手术中的临床应用[J]. 中国癌症杂志, 2021, 31(4): 302-307.
[5]	曾　峰, 李　丹, 邵鑫鑫, 张能英, 陈星翰, 程晓明 . 基于SEER数据库构建1~2枚淋巴结阳性且乳房全切的老年早期乳腺癌患者不同腋窝手术方式的生存预测模型[J]. 中国癌症杂志, 2021, 31(4): 323-329.
[6]	杨柳松, 祝迎锋, 唐剑敏 . 上皮样胶质母细胞瘤10例报告并文献复习[J]. 中国癌症杂志, 2021, 31(2): 114-120.
[7]	李　飞, 宋　媛, 李　芳, 朱希燕, 何　明 . 食管胃交界部腺癌SiewertⅠ型和Ⅱ型胸外科手术治疗效果及预后研究[J]. 中国癌症杂志, 2021, 31(2): 143-150.
[8]	龙克艰, 杨　超, 吴　强, 查　炜. 甲状腺术中喉不返神经的解剖特点及神经监测的使用[J]. 中国癌症杂志, 2021, 31(10): 927-931.
[9]	王　迪, 陈　锋, 金艳玲, 孙志刚, 白珊珊, 崔晓楠, 张　斌. 原发性睾丸旁平滑肌肉瘤1例报告[J]. 中国癌症杂志, 2020, 30(9): 718-720.
[10]	陈飞儿 , 张　凤 , 谈振宇 , 夏庆华 , 包士三 , 陶　琨 , 董志恒 . 白细胞介素35和白细胞介素37与结直肠癌临床病理学特征及预后的相关性研究[J]. 中国癌症杂志, 2020, 30(6): 456-461.
[11]	薛　田, 盛　东, 颜婉惠, 蒋翔男, 李欢鸽, 李小秋. 滤泡性淋巴瘤预后因素的研究[J]. 中国癌症杂志, 2020, 30(5): 388-393.
[12]	石志强 , 邱鹏飞 , 刘雁冰 , 赵　桐 , 孙　晓 , 陈　鹏 , 王春建 , 张朝蓬 , 丛斌斌 , 王永胜 . HER2阳性和三阴性乳腺癌新辅助化疗后选择性避免腋窝手术分期的研究[J]. 中国癌症杂志, 2020, 30(3): 186-191.
[13]	孙阳阳,耿　翔,周晓莉,王更方,顾文贤,张旭东 . 原发性胃弥漫大B细胞淋巴瘤临床病理学观察及预后因素分析[J]. 中国癌症杂志, 2019, 29(9): 715-722.
[14]	朱序勤,贾淞淋,祁　洁,申雪芳,龙　江,缪长虹 . 影响胰腺癌根治术预后的围手术期相关因素的回顾性分析[J]. 中国癌症杂志, 2019, 29(7): 521-527.
[15]	刘永智, 赵永华, 姜海, 鲍丽萍, 吴威, 孙强, 姜汇川, 贾兆博, 郝世超. 基于SEER数据库的乳腺黏液腺癌临床病理学特征及生存分析[J]. 中国癌症杂志, 2019, 29(12): 955-960.